In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Pharma Markets: Adapt, Diversify, and Persist

Executive Summary

Emerging global markets are a hot topic in pharmaceutical circles these days, but until recently, most Westerners viewed them as a homogenous cluster. Few executives at corporate headquarters drew distinctions among the various countries, let alone the domestic and international players in those markets. As big pharma bumps up against growth constraints in its traditional markets, however, interest in the "rest of the world" is perking up. The largest pharmaceutical companies are all looking at the same promising half dozen or so emerging countries, but they are taking radically different approaches to tackling them and are moving at different paces.

You may also be interested in...



Bristol Tries Out New Selling Strategy With Yervoy Launch

Bristol-Myers Squibb is using a "new customer model" that takes a holistic approach to supporting Yervoy (ipilimumab), CEO Lamberto Andreotti told analysts on the company's first-quarter earnings call on April 28.

AZ Taps India's Torrent to Add Branded Generics in Emerging Markets

LONDON - To extend its reach in emerging markets, AstraZeneca PLC today said it had signed an agreement with India's Torrent Pharmaceuticals Ltd. for the rights to sell 18 undisclosed generic drugs in nine territories

AZ Taps India's Torrent to Add Branded Generics in Emerging Markets

Innovation-only AstraZeneca gets the branded generics religion, at least in emerging markets.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel